# T3011

Source: https://onco.cc/drugs/t3011/  
OnCo record `t3011` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

T3011 is an experimental small-molecule drug from ImmVira Pharma in phase 2 trials for melanoma, head and neck squamous cell carcinoma and sarcomas, aimed at PD-1 and PD-L1.

## Summary

T3011 is a small-molecule drug developed by ImmVira Pharma and Shanghai Pharmaceuticals. Its targets are PD-1 and PD-L1. ClinicalTrials.gov describes the intervention as: T3011 will be administered up to 4mL as an intratumoral injection given Q2W. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in melanoma, head and neck squamous cell carcinoma, sarcomas, non-small-cell lung cancer and bladder & urothelial cancer. The largest, NCT06971614, plans to enrol 160 participants with primary completion expected 2028-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: oncolytic virus (intratumoral oncolytic HSV-1, per the sponsor's pipeline page; registered as a drug on ClinicalTrials.gov)
- Mechanism: Small-molecule drug directed at PD-1 and PD-L1, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of T3011: https://clinicaltrials.gov/search?intr=T3011

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/)
- companies: [ImmVira Pharma](https://onco.cc/companies/immvira-pharma/)
- trials: [A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Adva](https://onco.cc/trials/nct04370587/), [A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC](https://onco.cc/trials/nct06971614/)

---
JSON: https://onco.cc/api/v1/entities/t3011.json